Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Schwartzberg L, Morrow G, Balu S, Craver C, Gayle J, Cox D. Schwartzberg L, et al. Among authors: balu s. Curr Med Res Opin. 2011 Aug;27(8):1613-22. doi: 10.1185/03007995.2011.596201. Epub 2011 Jun 22. Curr Med Res Opin. 2011. PMID: 21696263 Clinical Trial.
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D. Feinberg B, et al. Among authors: balu s. Support Care Cancer. 2012 Mar;20(3):615-23. doi: 10.1007/s00520-011-1140-x. Epub 2011 Mar 29. Support Care Cancer. 2012. PMID: 21761096
Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, DeLeon A, Elliott C, Korrer S. Schwartzberg LS, et al. Among authors: balu s. J Manag Care Spec Pharm. 2018 Oct;24(10):976-984. doi: 10.18553/jmcp.2018.17447. Epub 2018 Apr 24. J Manag Care Spec Pharm. 2018. PMID: 29687743 Free PMC article.
OBJECTIVE: To compare FN incidence and assess overall FN-related health care resource utilization and medical costs among U.S. patients with non-myeloid cancer who received filgrastim-sndz or filgrastim-ref during their first chemotherapy cycle. ...Mean (SD) FN-related tot …
OBJECTIVE: To compare FN incidence and assess overall FN-related health care resource utilization and medical costs among U.S. patien …
271 results